Key result
Anlotinib linked to a ~45% TRPG reduction in a patient with pulmonary tumor thrombotic microangiopathy.
Why the study?
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare malignancy-related complication with rapid progression of pulmonary hypertension and respiratory failure, and treatment options are limited mainly to imatinib therapy.
Does anlotinib improve pulmonary hypertension and respiratory dysfunction in patients with PTTM associated with gastric carcinoma?
Case Report (n=1)
No
Does anlotinib improve pulmonary hypertension and respiratory dysfunction in patients with PTTM associated with gastric carcinoma?
Anlotinib may be a candidate drug for treating pulmonary hypertension and respiratory failure caused by Pulmonary Tumor Thrombotic Microangiopathy (PTTM).
BACKGROUND: Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare malignancy-related respiratory complication, demonstrating rapid progression of pulmonary hypertension (PH) and respiratory failure. Although a number of treatments have been attempted for patients diagnosed with or suspected of having PTTM, successful-treated cases of PTTM were mainly from imatinib therapy, which was a PDGF receptor inhibitor. Anlotinib was a novel tyrosine kinase inhibitor that targets VEGFR, FGFR, PDGFR, and c-kit. CASE PRESENTATION: We reported a patient of PTTM associated with gastric carcinoma, whom were treated with anlotinib, thereby exhibiting significant improvement of PH and respiratory dysfunction. CONCLUSION: Our case provides a new understanding of therapy to PTTM, with implications for defining anlotinib as candidate drug for PTTM. Clinical diagnosis and prompt initiation of anlotinib might be one of the strategies in patients with unstable PTTM.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a case report in Pulmonary Tumor Thrombotic Microangiopathy (PTTM) associated with gastric carcinoma (n=1). Anlotinib was evaluated on Pulmonary hypertension and hypoxia (TRPG, D-dimer, NT-proBNP, NYHA class). Anlotinib dramatically improved pulmonary hypertension and hypoxia in a patient with pulmonary tumor thrombotic microangiopathy associated with gastric carcinoma, reducing TRPG from 64 to 35 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: